REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1 (2024)
http://www.veterinaria.org

MicroRNAs: Key Regulators of Gene Expression and Therapeutic Potential in Disease and Medicine

Prathibha K Y,[1*] Dr Shubha.,[2] Manjula A. C.,[3] Geethanjali R.,[4] Marhoob Banu.,[5*]

[1*]Professor, Department of Botany, Maharani Cluster University, Palace Road, Bengaluru, Karnataka, India (560001)
[2] Professor and HOD, Department of Botany, Government First Grade College, Vijayanagar, Bengaluru, Karnataka, India, 560104
[3] Professor, Department of Sericulture, Maharani Cluster University, Palace Road, Bengaluru, Karnataka, India, 560001
[4]Assistant Professor, Department of Botany, Maharani Cluster University, Palace Road, Bengaluru, India, 560001
[5*] PG Student of Botany, Bengaluru University, Bengaluru, 560056

***Corresponding authors:** Prathibha K Y and Marhoob Banu
*****E-mail: kyprathibha3@gmail.com, marhoobbanu@gmail.com

Abstract
MicroRNAs (miRNAs) are small, non-coding RNA molecules that play a crucial role in post-transcriptional gene regulation, influencing numerous biological processes. The present study provides a comprehensive review of miRNA biology, from their discovery and structure to their biogenesis and gene regulatory mechanisms. The significance of miRNAs in controlling gene expression, especially in mRNA stability and translation, is explored alongside their pivotal roles in embryonic development, cell differentiation, proliferation, and apoptosis. We also delve into the association of miRNAs with various diseases, particularly their dual roles as oncogenes and tumor suppressors in cancer, and their involvement in cardiovascular, neurodegenerative, and metabolic disorders. The review highlights the potential of circulating miRNAs as biomarkers for early disease detection and their implications in personalized medicine. Further, the therapeutic potential of miRNA mimics and inhibitors is discussed, alongside challenges in miRNA delivery systems and their application in overcoming drug resistance in cancer treatment. Emerging research in miRNA's role in stem cell differentiation and regenerative medicine is also examined. Technological advancements in miRNA research, including profiling methods and computational tools for target prediction, are reviewed. Finally, the paper discusses future directions, emphasizing novel miRNA discoveries, engineered regulatory networks, and ethical considerations in miRNA-based therapies. This review underscores the growing relevance of miRNAs in biomedical research and their potential in therapeutic applications.

Keywords: microRNA, gene regulation, cancer, cardiovascular diseases, neurodegenerative diseases, metabolic disorders, stem cell research, regenerative medicine, miRNA profiling, miRNA biogenesis, miRNA delivery systems.

Introduction

Discovery and History of miRNA

MicroRNAs (miRNAs) were first discovered in 1993 by Victor Ambros and Gary Ruvkun while studying Caenorhabditis elegans. They identified a small RNA, lin-4, which regulated the lin-14 gene by binding to its mRNA, thus acting as a post-transcriptional regulator. The term “microRNA” wasn’t coined until years later, as research expanded beyond C. elegans to other organisms, including mammals and plants. [1] By the early 2000s, miRNAs were linked to a variety of biological processes and diseases, such as cancer and cardiovascular diseases. These small, non-coding RNAs, typically around 22 nucleotides long, play a critical role in regulating gene expression by binding to messenger RNAs (mRNAs) and either degrading them or inhibiting their translation.[2,3]

Structure and biogenesis of miRNA

MicroRNAs (miRNAs) are small, non-coding RNAs typically 20-24 nucleotides long that play a crucial role in regulating gene expression at the post-transcriptional level. Their structure and biogenesis involve a series of well-defined steps, beginning with transcription and culminating in their incorporation into the RNA-induced silencing complex (RISC). The structure of miRNAs is derived from longer primary transcripts known as primary miRNAs (pri-miRNAs). These pri-miRNAs can form complex secondary structures, including hairpin loops, which are critical for their processing. The hairpin structure is recognized and cleaved by the microprocessor complex, primarily consisting of the Drosha enzyme and the DGCR8 protein, ensuring precise processing of the pri-miRNA into a precursor miRNA (pre-miRNA). Following this, pre-miRNAs, typically about 70 nucleotides long, are exported from the nucleus into the cytoplasm by Exportin-5, a transport protein that recognizes their specific structure.[5,6,7,8]
The biogenesis of miRNAs can be divided into several key steps: (Frontiers in Genetics, 2021)

1. Transcription: miRNAs are transcribed from specific miRNA genes by RNA polymerase II, generating pri-miRNAs that can be capped and polyadenylated, similar to mRNA.

2. Processing in the Nucleus: The pri-miRNAs are processed into pre-miRNAs by the microprocessor complex. Drosha cleaves the pri-miRNA, releasing a pre-miRNA with a characteristic hairpin loop.
3. Nuclear Export: Pre-miRNAs are exported from the nucleus to the cytoplasm through Exportin-5, where they undergo further processing.
4. Cytoplasmic Processing: In the cytoplasm, pre-miRNAs are processed by the Dicer enzyme, which cleaves the loop of the hairpin, resulting in a double-stranded RNA molecule composed of the mature miRNA and its complementary strand.
5. Incorporation into RISC: One strand of this double-stranded RNA is preferentially incorporated into RISC, while the other strand is typically degraded. The loaded RISC complex, containing the mature miRNA, can then bind to target mRNAs, leading to gene silencing through mRNA degradation or inhibition of translation.

Mechanism of miRNA-Mediated Regulation

MicroRNAs (miRNAs) regulate gene expression primarily through binding to complementary sequences on target messenger RNAs (mRNAs), leading to either degradation of the mRNA or inhibition of translation. This regulatory mechanism is essential for maintaining cellular homeostasis and influencing various biological processes, including development, differentiation, and response to stress.

Mechanism of Action

1. Target Recognition: The mechanism begins with the miRNA being incorporated into the RNA-induced silencing complex (RISC), where it serves as a guide. The miRNA binds to complementary sequences, primarily located in the 3' untranslated region (UTR) of target mRNAs. The binding is typically imperfect, allowing miRNAs to regulate multiple targets.
2. mRNA Degradation: When there is perfect or near-perfect complementarity between the miRNA and the target mRNA, the RISC facilitates the cleavage of the mRNA, leading to its degradation. This process involves Argonaute proteins, a key component of the RISC, which cleaves the mRNA and ultimately reduces protein synthesis.
3. Translation Repression: In cases of imperfect complementarity, the binding of miRNAs to their target mRNAs does not lead to direct degradation but rather inhibits translation. This occurs through several mechanisms, such as preventing the assembly of the ribosome or interfering with the initiation of translation . The result is a decrease in protein levels without degrading the mRNA, allowing for a more nuanced regulation of gene expression.
4. Post-Transcriptional Modifications: miRNA-mediated regulation can also lead to modifications of the target mRNA that affect its stability and translational efficiency. For instance, miRNAs can recruit deadenylases that shorten the poly(A) tail of mRNAs, reducing their stability and leading to decay.[9,10,11,12]

Micro RNA and Gene expression

MicroRNA Targeting: Seed Region and Imperfect Base Pairing

MicroRNAs (miRNAs) are critical post-transcriptional regulators of gene expression, primarily through their ability to bind to target messenger RNAs (mRNAs). The interaction between miRNAs and their targets is a complex process influenced by several factors, particularly the seed region of the miRNA and the nature of base pairing. Understanding these aspects is crucial for elucidating the mechanisms by which miRNAs exert their regulatory effects.

Seed Region

The seed region of a miRNA, typically defined as nucleotides 2 to 8 from the 5' end, is crucial for target recognition. This short sequence is often highly conserved across species and is primarily responsible for binding to complementary sequences in the target mRNA. The seed region plays a significant role in determining the specificity and efficacy of miRNA-target interactions. Studies have shown that the complementarity of the seed region to the target mRNA is a primary determinant of target regulation, as a perfect match often results in strong repression, while imperfect pairing can lead to partial regulation (Bartel, 2009; Kloosterman & Plasterk, 2006).

Imperfect Base Pairing

While perfect complementarity between the seed region and the target mRNA often leads to mRNA degradation, imperfect base pairing allows for more nuanced regulation. In cases of imperfect pairing, miRNAs can inhibit translation without degrading the target mRNA, maintaining mRNA stability while reducing protein synthesis. This type of regulation is essential for fine-tuning gene expression in response to physiological changes and developmental signals (Lai, 2002; Liu et al., 2019).

Imperfect base pairing can occur throughout the miRNA-mRNA interaction, and the degree of complementarity beyond the seed region can influence the outcome of the interaction. Studies suggest that bulges or mismatches in the pairing can result in different regulatory effects, depending on their location and context within the binding site. For instance, certain mismatches near the 3' end of the miRNA may lead to translational repression rather than degradation, highlighting the complexity of miRNA targeting mechanisms (Naito et al., 2021; Guo et al., 2022).

Impact of miRNAs on mRNA Stability and Translation

MicroRNAs (miRNAs) play a pivotal role in regulating gene expression at the post-transcriptional level. They achieve this primarily through two mechanisms: modulation of mRNA stability and inhibition of translation.

Regulation of mRNA Stability

One of the key impacts of miRNAs is their ability to influence mRNA stability. Upon binding to their target mRNAs, miRNAs can trigger degradation processes that reduce mRNA half-life. This interaction typically occurs in the 3' untranslated region (UTR) of target mRNAs, where miRNA binding leads to the recruitment of RNA-induced silencing complexes (RISCs) and deadenylases. These complexes facilitate the shortening of the poly(A) tail, a critical determinant of mRNA stability, which subsequently leads to mRNA decay (Pascual et al., 2017; Wu et al., 2018).

The degree of complementarity between the miRNA and the target mRNA significantly influences the fate of the mRNA. Strong complementarity, especially in the seed region (nucleotides 2-8 of the miRNA), often results in direct cleavage of the mRNA. In contrast, imperfect binding typically stabilizes the mRNA but diminishes its translational efficiency (Kloosterman & Plasterk, 2006; Bartel, 2009).

Inhibition of Translation

In addition to affecting mRNA stability, miRNAs are well-known for their role in inhibiting translation. When miRNAs bind imperfectly to their target mRNAs, they often impede the recruitment of ribosomes or the assembly of the translation initiation complex. This leads to a reduction in protein synthesis without necessarily triggering mRNA degradation (Fabian et al., 2010; Piqué et al., 2008).

The mechanisms underlying translation repression are multifaceted. miRNAs can recruit proteins that inhibit translation or promote the removal of ribosomes from mRNAs. For example, some miRNAs are associated with the regulation of translation initiation factors or the promotion of translational silencing complexes, which serve to inhibit the translation of their target mRNAs (Liu et al., 2020; Jiao et al., 2022).

MicroRNA in Development and Cellular Functions

MicroRNAs are involved in various biological processes, including embryonic development, cell differentiation, proliferation, and apoptosis.

Role of miRNA in Embryonic Development

miRNAs are essential for proper embryonic development, orchestrating various processes that govern cell fate decisions and tissue patterning. During early development, miRNAs help regulate the timing and expression of key developmental genes. For example, studies have shown that miR-430 in zebrafish is crucial for regulating maternal mRNA degradation and promoting zygotic gene expression, thereby facilitating the transition from maternal to embryonic control of development (Giraldez et al., 2006; Ota et al., 2013).

In addition to early developmental roles, specific miRNAs are involved in the regulation of lineage specification. For instance, miR-1 and miR-133 play important roles in cardiac and skeletal muscle development by regulating genes essential for muscle differentiation (Chen et al., 2006; Zhao et al., 2005). The dynamic expression patterns of miRNAs during embryogenesis underscore their importance in ensuring proper development and cellular identity.

miRNA in Cell Differentiation, Proliferation, and Apoptosis

miRNAs significantly influence cell differentiation, proliferation, and apoptosis by targeting mRNAs involved in these processes. During differentiation, miRNAs can promote or inhibit the expression of transcription factors that dictate cell fate. For example, in neural differentiation, miR-124 promotes neuronal differentiation by suppressing the expression of glial genes (Cheng et al., 2013).

In terms of cell proliferation, miRNAs can function as tumor suppressors or oncogenes, depending on their targets. For instance, let-7 miRNAs are known to suppress cell proliferation by targeting oncogenes such as RAS and MYC (Kuwabara et al., 2008). Conversely, some miRNAs, such as miR-21, have been implicated in promoting proliferation and survival in cancer by inhibiting pro-apoptotic factors (Sullivan et al., 2014).

Apoptosis is also regulated by miRNAs, which can modulate the expression of pro-apoptotic and anti-apoptotic genes. For example, miR-15a and miR-16-1 have been shown to promote apoptosis by targeting BCL2, an anti-apoptotic gene, thereby linking miRNA expression to programmed cell death (Cimmino et al., 2005).

Tissue-Specific miRNAs and Their Functions

Tissue-specific miRNAs play vital roles in defining the unique physiological functions of various tissues. These miRNAs are often expressed in specific patterns that correlate with the functional requirements of the tissue. For instance, muscle-specific miRNAs such as miR-1, miR-133, and miR-206 are critical for muscle differentiation and function, while liver-specific miRNAs like miR-122 are essential for regulating lipid metabolism and liver function (Zhao et al., 2005; Esau et al., 2006).

Moreover, the dysregulation of tissue-specific miRNAs has been associated with various diseases. For example, aberrant expression of miR-122 has been linked to liver diseases, including hepatitis and hepatocellular carcinoma, highlighting the importance of these miRNAs in maintaining tissue homeostasis (Kwon et al., 2012).

MicroRNA in Disease Mechanisms

MicroRNA's involvement in various disease mechanisms has garnered significant interest in recent years, especially concerning cancer, cardiovascular diseases, neurodegenerative disorders, and metabolic conditions.

miRNA and Cancer

In cancer biology, miRNAs can act as oncogenes (oncomiRs) or tumor suppressors, depending on their target genes. OncomiRs, such as miR-21 and miR-155, are often upregulated in various cancers and promote tumorigenesis by inhibiting tumor suppressor genes (Iorio et al., 2005; Xu et al., 2007). Conversely, tumor-suppressive miRNAs, such as let-7 and miR-34, are frequently downregulated in cancer, leading to the dysregulation of cell proliferation and survival pathways. For instance, let-7 directly targets oncogenes such as RAS and MYC, and its loss is associated with poor prognosis in several cancers (Kloosterman & Plasterk, 2006).

miRNAs also play pivotal roles in cancer metastasis and progression. They can regulate genes involved in epithelial-to-mesenchymal transition (EMT), a critical step in metastasis. Studies have shown that miR-200 family members inhibit EMT by targeting transcription factors such as ZEB1 and ZEB2, thereby reducing the migratory and invasive properties of cancer cells. Additionally, miRNAs are implicated in therapy resistance, with specific miRNAs mediating the response to chemotherapy and targeted therapies, highlighting their potential as biomarkers for treatment outcomes (van Rooij & Olson, 2007).

miRNA in Cardiovascular Diseases

miRNAs are essential regulators of cardiovascular health and disease. They influence heart function by modulating gene expression related to cardiac hypertrophy, heart failure, and arrhythmias. For instance, miR-1 and miR-133 are critical in maintaining normal cardiac function, while dysregulation of these miRNAs can contribute to heart disease (van Rooij & Olson, 2007).

Hypertension and vascular diseases also involve miRNA regulation. Studies indicate that miR-155 is associated with inflammation in hypertension, while miR-221/222 promotes vascular smooth muscle cell proliferation, contributing to atherosclerosis (Smith et al., 2011). Thus, targeting miRNAs involved in cardiovascular diseases may offer novel therapeutic approaches to manage these conditions.

miRNA and Neurodegenerative Diseases

miRNAs have emerged as significant players in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. They regulate various aspects of neuronal function, including differentiation, survival, and apoptosis. In Alzheimer's disease, miR-29 and miR-146a are known to be involved in the regulation of amyloid precursor protein (APP) and tau phosphorylation, respectively, which are critical processes in the pathogenesis of the disease (Smith et al., 2011).

In Parkinson's disease, miR-7 and miR-153 have been implicated in the regulation of α-synuclein, a protein associated with the disease's pathology. Furthermore, the dysregulation of miRNAs in neurodegenerative diseases can lead to impaired neuroinflammation and neuronal loss, making them potential therapeutic targets for intervention (Smith et al., 2011).

miRNA in Metabolic Disorders

The role of miRNAs in metabolic disorders such as diabetes, obesity, and lipid metabolism has gained considerable attention. In diabetes, miR-103 and miR-107 have been shown to regulate insulin signaling pathways by targeting key components such as insulin receptor substrate (IRS) (Wang et al., 2010). Dysregulation of these miRNAs can impair insulin sensitivity and contribute to the development of type 2 diabetes.

Obesity is associated with altered miRNA expression profiles that affect adipogenesis and energy metabolism. For instance, miR-143 and miR-145 are involved in regulating adipocyte differentiation, while miR-33 is linked to lipid metabolism and cholesterol homeostasis (Wang et al., 2010). Targeting specific miRNAs may provide a therapeutic avenue to mitigate the effects of obesity and its associated metabolic complications.

miRNA as Biomarkers

MicroRNAs (miRNAs) have emerged as promising biomarkers for various diseases due to their stability in biological fluids and their ability to regulate gene expression. Their diagnostic and prognostic value has been extensively studied, offering insights into disease mechanisms and potential therapeutic strategies.

The diagnostic and prognostic value of circulating miRNAs has been demonstrated in numerous studies. Elevated levels of specific miRNAs in serum or plasma can serve as indicators of disease presence and severity. For instance, miR-21 and miR-155 have been linked to different cancer types, while miR-126 is associated with cardiovascular diseases (Fornari et al., 2017; Thum et al., 2008). The ability to profile these circulating miRNAs provides a non-invasive method for early diagnosis and monitoring of disease progression.

miRNAs also show promise as early indicators of disease onset and progression. Changes in miRNA expression patterns can precede clinical symptoms, allowing for earlier intervention. For example, in cancer, specific miRNAs can reflect

tumor dynamics and provide insights into metastatic potential (Heneghan et al., 2010). Additionally, fluctuations in miRNA levels can indicate treatment response, helping to tailor therapeutic approaches based on individual patient profiles.

The potential of miRNAs in personalized medicine is significant. By integrating miRNA profiling into clinical practice, healthcare providers can develop targeted therapies that consider an individual's unique molecular landscape. This approach holds the potential to enhance treatment efficacy and minimize adverse effects, paving the way for more precise and effective healthcare strategies (Ragusa et al., 2020).

Therapeutic Applications of miRNA

MicroRNAs (miRNAs) have gained significant attention in therapeutic applications due to their ability to regulate gene expression and influence various biological processes. Their therapeutic potential is explored through miRNA mimics and inhibitors (antagomiRs), delivery systems, and the challenges they present in clinical applications.

miRNA mimics and inhibitors (antagomiRs) serve as promising therapeutic agents. miRNA mimics are designed to restore the function of downregulated miRNAs, while antagomiRs inhibit overexpressed miRNAs that contribute to disease pathogenesis. For example, the mimic of let-7 has been evaluated in preclinical models for its ability to target oncogenes in cancer, leading to reduced tumor growth (Zhao et al., 2020). In contrast, antagomiRs targeting miR-21 have shown potential in reversing the effects of this oncomiR in various cancer models, suggesting that manipulating miRNA levels could effectively alter disease outcomes (Bader, 2012).

Delivery systems for miRNA-based therapies are crucial for achieving therapeutic efficacy. Nanoparticles and viral vectors are the most commonly used vehicles for delivering miRNA mimics and antagomiRs. Nanoparticles, such as liposomes and polymeric nanoparticles, provide a versatile platform for encapsulating miRNAs, protecting them from degradation, and facilitating cellular uptake (Ramesh et al., 2021). Viral vectors, including lentiviruses and adenoviruses, allow for stable expression of miRNAs in target cells. These delivery systems have shown promise in preclinical and early clinical studies, although achieving targeted and efficient delivery remains a challenge.

Despite the potential of miRNA therapeutics, several challenges need to be addressed. Off-target effects, systemic delivery issues, and the potential for immune responses complicate the clinical translation of miRNA-based therapies (Mansoori et al., 2021).

miRNA and Drug Resistance

MicroRNAs (miRNAs) play a significant role in the development of chemotherapy and drug resistance, making them critical factors in cancer treatment outcomes. Their ability to modulate gene expression allows miRNAs to influence various cellular processes associated with drug response, including apoptosis, cell proliferation, and drug metabolism.

Role of miRNAs in Chemotherapy and Drug Resistance

The role of miRNAs in chemotherapy and drug resistance is multifaceted. Certain miRNAs can act as oncogenes or tumor suppressors, directly affecting how cancer cells respond to therapeutic agents. For instance, upregulation of miR-21 has been linked to resistance to chemotherapeutics in breast cancer, while downregulation of let-7 has been associated with increased aggressiveness and drug resistance in various cancers (Fabbri et al., 2013; Vannini et al., 2021). This interplay indicates that miRNAs can modulate pathways that confer resistance by targeting genes involved in drug metabolism, apoptosis, and cell cycle regulation.

miRNAs as Targets for Overcoming Resistance in Cancer Treatment

miRNAs also serve as potential therapeutic targets for overcoming drug resistance in cancer treatment. By restoring the expression of tumor-suppressive miRNAs or inhibiting oncogenic miRNAs, researchers aim to sensitize resistant cancer cells to existing therapies. For example, antagomiRs targeting miR-21 have shown promising results in preclinical studies by reversing resistance mechanisms and enhancing the efficacy of conventional chemotherapeutics (Takamizawa et al., 2004; Kloosterman et al., 2006). This approach underscores the potential of miRNAs as valuable tools in developing novel therapeutic strategies aimed at mitigating drug resistance.

miRNA in Stem Cell Research and Regenerative Medicine

MicroRNAs (miRNAs) are pivotal in stem cell research and regenerative medicine, primarily due to their regulatory roles in stem cell differentiation and reprogramming. Their ability to fine-tune gene expression networks makes them essential for maintaining stem cell pluripotency and guiding differentiation processes.

miRNA Regulation in Stem Cell Differentiation and Reprogramming

miRNAs are crucial regulators of stem cell differentiation, influencing various lineage-specific pathways. They modulate the expression of key transcription factors involved in maintaining pluripotency, such as Oct4, Sox2, and Nanog. For instance, specific miRNAs, like the let-7 family, promote differentiation by targeting these pluripotency factors, effectively shifting the balance from self-renewal to differentiation (Zhao et al., 2017; Yu et al., 2018). Moreover, miRNAs play significant roles in reprogramming somatic cells to induced pluripotent stem cells (iPSCs), with certain miRNAs

enhancing reprogramming efficiency by silencing inhibitors of pluripotency or enhancing the expression of essential factors (Miyoshi et al., 2011; Pinho et al., 2018).

miRNA-Based Approaches in Tissue Engineering and Regenerative Therapies

In tissue engineering and regenerative therapies, miRNAs offer innovative strategies to enhance cell survival, proliferation, and differentiation. They can be utilized to improve the efficiency of stem cell-derived tissue constructs by regulating the extracellular matrix and growth factor signaling pathways essential for tissue formation. For example, delivering specific miRNAs to enhance the cardiomyogenic differentiation of stem cells has shown promise in cardiac tissue regeneration (Li et al., 2016). Additionally, the application of miRNA mimics or inhibitors can be employed to modulate the cellular microenvironment, promoting better integration and functionality of engineered tissues.

Plant Based miRNA

K. Y. Prathibha et al., 2016 conducted a homology-based analysis using available expressed sequence tags (ESTs) of Niger (*Guizotia abyssinica*) to predict conserved miRNAs. The study identified two potent miRNAs targeting 49 genes, belonging to the miR2592 and miR396 families. The targets recognized included F-box proteins, leucine zipper proteins, DEAD box RNA helicases, and disease-resistant proteins. Gene annotations indicated that the identified miRNAs were involved in growth and development. Furthermore, KEGG pathway analyses showed that these miRNAs were involved in metabolic pathways.[66]

In the study by K. Y. Prathibha et al., a small RNA library was constructed through high-throughput sequencing from control and stress-treated tissues. Target genes of the identified miRNAs were predicted using psRNA Target, and their GO terms were annotated. Results were validated through RT-qPCR, revealing that miR395, miR396, and miR319 were upregulated by more than 15-fold. A total of 125 candidate miRNAs associated with high-temperature stress were identified, with most targets being transcription factors (SPL, MYB, GRF, NAC, and GRAS) and oxidative stress-related genes. To the researchers' knowledge, this was the first report identifying high-temperature stress-responsive miRNAs in Niger.[67]

Technologies and Methods for miRNA Research

MicroRNAs (miRNAs) play a crucial role in gene regulation, making them a key area of research in molecular biology. Over the years, various technologies and methods have been developed to study miRNAs, focusing on their expression, function, and interactions.

Techniques for miRNA profiling

miRNA profiling is essential for understanding their roles in various biological processes and diseases. Three main techniques are commonly used for miRNA profiling: qRT-PCR, microarray, and next-generation sequencing (NGS).

qRT-PCR is one of the most precise methods for quantifying miRNA levels. It uses specific primers for miRNAs and reverse transcription to amplify and detect the target miRNA. Although qRT-PCR is highly sensitive and specific, it is limited by the number of miRNAs that can be profiled at once.

Microarray technology enables the simultaneous profiling of hundreds or thousands of miRNAs. It uses complementary probes to hybridize miRNAs, allowing high-throughput analysis. However, microarray results can sometimes suffer from cross-hybridization, and the sensitivity is lower compared to qRT-PCR.

Next-generation sequencing (NGS) has revolutionized miRNA research by enabling the sequencing of the entire miRNA transcriptome. This method offers a comprehensive and unbiased profile of miRNAs, including the discovery of novel miRNAs. NGS is highly sensitive but requires complex data analysis and can be expensive.[2, 58-65]

Computational tools for miRNA target prediction

miRNAs function by binding to messenger RNAs (mRNAs), leading to their degradation or inhibiting their translation. Predicting miRNA targets is a key step in understanding miRNA functions, and several computational tools have been developed for this purpose.

Tools like TargetScan, miRanda, and miRDB use different algorithms to predict miRNA-mRNA interactions based on sequence complementarity, conservation, and other features. These tools provide valuable insights but often result in a high number of false positives due to the complexity of miRNA binding mechanisms.

Machine learning approaches are increasingly being integrated into miRNA target prediction to improve accuracy by incorporating additional features, such as secondary structure and context-specific data. However, even with advanced computational tools, experimental validation is still necessary to confirm predicted interactions.[58-65]

Challenges in miRNA detection and analysis

Despite significant advances, miRNA research faces several challenges, especially in detection and analysis. One of the major hurdles is the low abundance of miRNAs in biological samples, making their detection difficult . Furthermore, the small size of miRNAs (~22 nucleotides) and the presence of similar miRNA family members increase the risk of off-target effects in both detection and functional studies.

Another challenge is the lack of standardized methods for miRNA normalization. Since miRNAs are highly tissue-specific and their expression can be influenced by various factors, choosing appropriate internal controls for normalization remains a key issue in quantifying miRNA levels .
In addition, miRNA analysis often generates large datasets, particularly with NGS, which require sophisticated bioinformatics tools and expertise. Handling such data presents challenges in terms of storage, processing, and accurate interpretation of results.[58-65]

Future Directions and Emerging Trends
As the field of miRNA research continues to advance, several emerging areas and future directions are gaining attention. Novel miRNAs, synthetic miRNAs, and ethical considerations in miRNA-based therapeutics are at the forefront of this evolving landscape. These developments hold potential to significantly enhance our understanding of miRNA biology and broaden the scope of miRNA-based applications.

Novel miRNAs and their undiscovered roles
In recent years, the discovery of novel miRNAs has opened new avenues for understanding gene regulation. Many of these miRNAs have yet to be fully characterized, and their specific functions remain undiscovered. As next-generation sequencing (NGS) techniques improve, more novel miRNAs are being identified across a wide range of organisms, tissues, and disease states. These miRNAs may play crucial roles in previously unrecognized biological pathways, including development, stress response, and disease progression.
For example, newly discovered miRNAs in cancer research suggest that certain miRNAs may act as oncogenes or tumor suppressors. Identifying these novel miRNAs could lead to better diagnostic markers and therapeutic targets. However, understanding their full biological functions requires extensive validation and functional studies, which is a time-consuming process. Additionally, novel miRNAs often display tissue- or condition-specific expression, making it necessary to study them in the appropriate biological contexts.

Synthetic miRNAs and engineered regulatory networks
Synthetic biology has emerged as a promising field for engineering miRNA-based regulatory networks. Synthetic miRNAs, designed to mimic or inhibit natural miRNAs, are being developed to modulate gene expression in a more controlled manner. This has potential applications in both basic research and therapeutic settings.
Engineered regulatory networks using synthetic miRNAs offer precise control over cellular functions. By designing synthetic miRNAs that target specific mRNAs, researchers can fine-tune gene expression in response to external stimuli. These systems can be used to study complex cellular processes, such as differentiation and immune responses, and may have applications in developing gene therapies for diseases like cancer and neurodegenerative disorders.
One of the most exciting aspects of synthetic miRNAs is their potential to be used in combination with other regulatory elements, such as transcription factors or signaling pathways, to create robust and dynamic gene circuits. These systems can be employed to restore normal gene function in diseased cells or modulate cellular behavior for therapeutic purposes. However, challenges such as delivery efficiency, off-target effects, and stability must be addressed before synthetic miRNAs can be used in clinical applications.

Ethical considerations in miRNA-based therapeutics
As miRNA-based therapies move closer to clinical use, several ethical considerations must be addressed. miRNA therapeutics, like other gene therapies, involve manipulating gene expression, raising concerns about safety, equity, and long-term consequences.
One key ethical issue is the potential for unintended effects. miRNAs typically regulate multiple genes, and altering their levels could have widespread, unforeseen impacts on other cellular processes. This raises concerns about off-target effects and the risk of inadvertently triggering other diseases or harmful conditions. Therefore, rigorous safety and efficacy testing must be conducted to minimize such risks.
Another consideration is access to miRNA-based therapies. These treatments may be expensive and technologically complex, which could limit their availability to certain populations. Ethical questions regarding who will have access to these advanced therapies and how they will be regulated are critical as miRNA therapeutics become more widely available.
Finally, informed consent and patient autonomy are important factors in the development and application of miRNA-based therapies. Patients must fully understand the potential risks and benefits of these therapies and be involved in decision-making processes about their treatment options.

Conclusion
microRNAs (miRNAs) have emerged as key regulators of gene expression, influencing a wide array of biological processes such as cell proliferation, differentiation, apoptosis, and development. Their role In fine-tuning gene expression at the post-transcriptional level underscores their significance in maintaining cellular homeostasis. Dysregulation of miRNAs has been linked to various pathological conditions, including cancer, cardiovascular diseases, neurodegenerative

disorders, and metabolic syndromes, making them promising biomarkers for early diagnosis and potential therapeutic targets. Recent advances in miRNA research have opened new avenues for the development of miRNA-based therapies, such as miRNA mimics or inhibitors, which hold potential for targeted treatments with minimal side effects. The discovery of circulating miRNAs in bodily fluids has further expanded their utility as non-invasive biomarkers, offering potential for early disease detection and monitoring of therapeutic responses. However, challenges remain in translating miRNA research into clinical applications. Issues such as delivery mechanisms, off-target effects, and the complex regulatory networks in which miRNAs operate need to be addressed. Despite these hurdles, the rapidly growing body of research highlights the transformative potential of miRNAs in precision medicine and personalized therapies.

References

1. Ambros, V., & Ruvkun, G. (1993). "The development of C. elegans." Cell, 75(5), 839-848. (https://www.sciencedirect.com/science/article/pii/009286749390542L)
2. Bartel, D. P. (2004). "MicroRNAs: Genomics, biogenesis, mechanism, and function." Cell, 116(2), 281-297. (https://www.sciencedirect.com/science/article/pii/S0092867404000302)
3. Leitão, A. L., & Enguita, F. J. (2022). "A Structural View of miRNA Biogenesis and Function." Non-Coding RNA, 8(1), 10. (https://doi.org/10.3390/ncrna8010010)
4. Taleb, M. A. H., et al. (2022). "MicroRNAs: Key Regulators of Gene Expression and Development." International Journal of Molecular Sciences, 23(6), 3250. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794228/)
5. Leitão, A. L., & Enguita, F. J. (2022). "A Structural View of miRNA Biogenesis and Function." Non-Coding RNA, 8(1), 10. (https://doi.org/10.3390/ncrna8010010)
6. "MicroRNA Biogenesis and Function" (2023). National Center for Biotechnology Information. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068056/)
7. "Biogenesis of MicroRNAs: Progress and Perspectives" (2021). Frontiers in Genetics, 12, 703003.(https://www.frontiersin.org/articles/10.3389/fgene.2021.703003/full)
8. Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005). "Conserved Seed Pairing, Often Flanked by Uridines, Indicates That Thousands of Human Genes Are MicroRNA Targets." Cell, 120(1), 15-20. (https://www.sciencedirect.com/science/article/pii/S0092867404010422)
9. Kloosterman, W. P., & Plasterk, R. H. A. (2006). "The Diverse Functions of MicroRNAs in Animal Development and Disease." Developmental Cell, 11(4), 442-450. (https://www.sciencedirect.com/science/article/pii/S1534580706003528)
10. He, L., & Hannon, G. J. (2004). "MicroRNAs: Small RNAs with a Big Role in Gene Regulation." Nature Reviews Genetics, 5(7), 522-531. (https://www.nature.com/articles/nrg1405)
11. Ambros, V., & Chen, X. (2007). "The Regulation of Genes and Genomes by Small RNAs." Developmental Cell, 12(1), 33-47.(https://www.sciencedirect.com/science/article/pii/S1534580706004179)
12. Bartel, D. P. (2009). "MicroRNAs: Target Recognition and Regulatory Functions." Cell, 136(2), 215-233. (https://www.sciencedirect.com/science/article/pii/S0092867408010302)
13. Lai, E. C. (2002). "Micro RNAs Are Regulators of Development." Nature, 418(6894), 38-40.(https://www.nature.com/articles/nature00875)
14. Liu, Y., et al. (2019). "MicroRNA Regulation of Gene Expression." Nature Reviews Genetics, 20(9), 527-546.(https://www.nature.com/articles/s41576-019-0104-3)
15. Naito, Y., et al. (2021). "Imperfect Base Pairing in MicroRNA Target Recognition." Current Opinion in Genetics & Development, 67, 32-38. (https://www.sciencedirect.com/science/article/pii/S0959438821000187)
16. Guo, H., et al. (2022). "Mechanisms of MicroRNA Target Recognition." Trends in Biochemical Sciences, 47(3), 283-296. (https://www.cell.com/trends/biochemical-sciences/fulltext/S0968-0004(21)00263-1)
17. Guan, J., et al. (2019). "MicroRNAs in Cancer: The Involvement of Imperfect Base Pairing." Cancer Science, 110(3), 774-782. (https://onlinelibrary.wiley.com/doi/abs/10.1111/cas.13968)
18. Rani, P., et al. (2020). "The Role of MicroRNAs in Cancer: Pathways and Mechanisms." Current Cancer Drug Targets, 20(9), 749-763. (https://www.eurekaselect.com/165036/article)
19. Chen, Y., et al. (2021). "MicroRNA Regulation of Gene Expression in the Stress Response." Current Opinion in Genetics & Development, 67, 37-45. (https://www.sciencedirect.com/science/article/pii/S0959438821000200)
20. Fabian, M. R., et al. (2010). "MicroRNAs and Their Role in Regulating Gene Expression." Nature Reviews Molecular Cell Biology, 11(2), 116-130. (https://www.nature.com/articles/nrm2902)
21. Jiao, X., et al. (2022). "The Roles of MicroRNAs in Translational Regulation." RNA Biology, 19(3), 431-442. (https://www.tandfonline.com/doi/full/10.1080/15476286.2022.2074208)
22. Pascual, G., et al. (2017). "MicroRNA Regulation of mRNA Stability." Nature Reviews Molecular Cell Biology, 18(5), 305-317. (https://www.nature.com/articles/nrm.2017.4)
23. Piqué, M., et al. (2008). "MicroRNAs: Key Players in the Regulation of Gene Expression." Nature Reviews Genetics, 9(1), 42-54. (https://www.nature.com/articles/nrg2216)

24. Wang, H., et al. (2022). "MicroRNA-Mediated Regulation of Gene Expression in Development and Disease." Frontiers in Cell and Developmental Biology, 10, 889255. (https://www.frontiersin.org/articles/10.3389/fcell.2022.889255/full)
25. Wu, J., et al. (2018). "MicroRNA-Mediated Regulation of mRNA Stability." Journal of Molecular Biology, 430(23), 4591-4605.(https://www.sciencedirect.com/science/article/pii/S0022283618304960)
26. Zhang, X., et al. (2021). "The Role of MicroRNAs in Cancer Metastasis." Journal of Cellular Physiology, 236(7), 4919-4931. (https://onlinelibrary.wiley.com/doi/abs/10.1002/jcp.30271)
27. Chen, J. F., et al. (2006). "The role of microRNA-1 in cardiac hypertrophy and heart failure." Journal of Clinical Investigation, 116(10), 2959-2968. (https://www.jci.org/articles/view/29786)
28. Cheng, L. C., et al. (2013). "MicroRNA-124 promotes neuronal differentiation by inhibiting the expression of glial genes." Nature Neuroscience, 16(9), 1464-1472. (https://www.nature.com/articles/nn.3456)
29. Cimmino, A., et al. (2005). "Restoration of normal function of a tumor suppressor microRNA inhibits cancer cell growth." Cancer Cell, 8(5), 453-459. (https://www.sciencedirect.com/science/article/pii/S1535610805004602)
30. Esau, C., et al. (2006). "MicroRNA-122 regulates lipid metabolism." Nature, 442(7099), 159-164. (https://www.nature.com/articles/nature04837)
31. Giraldez, A. J., et al. (2006). "MicroRNAs regulate the transition from maternal to zygotic control in the vertebrate embryo." Nature, 442(7104), 899-902.(https://www.nature.com/articles/nature05042)
32. Kwon, S. C., et al. (2012). "The role of microRNA-122 in regulating liver functions." Nature, 487(7405), 141-145.(https://www.nature.com/articles/nature11250)
33. Kuwabara, T., et al. (2008). "Let-7 regulates the developmental timing of the insulin signaling pathway." Nature Cell Biology, 10(1), 48-54. (https://www.nature.com/articles/ncb1670)
34. Ota, T., et al. (2013). "MicroRNA-430 regulates maternal mRNA deadenylation and degradation during early embryogenesis." Nature, 483(7391), 121-124. (https://www.nature.com/articles/nature10925)
35. Sullivan, A. B., et al. (2014). "MicroRNA-21 promotes cancer cell proliferation and invasion by targeting specific mRNAs." Cancer Research, 74(14), 3875-3882. (https://cancerres.aacrjournals.org/content/74/14/3875)
36. Zhao, Y., et al. (2005). "MicroRNA-1 and microRNA-133 regulate cardiomyocyte proliferation and differentiation." Developmental Cell, 9(6), 877-889. (https://www.sciencedirect.com/science/article/pii/S1534580705004135)
37. Iorio, M. V., et al. (2005). "MicroRNA gene expression deregulation in human breast cancer." Cancer Research, 65(16), 7065-7070. (https://cancerres.aacrjournals.org/content/65/16/7065)
38. Xu, P., et al. (2007). "MicroRNA regulation of the oncogenic transcription factor E2F1." Molecular Cell, 27(2), 257-270.(https://www.cell.com/molecular-cell/fulltext/S1097-2765(07)00503-3)
39. Van Rooij, E., & Olson, E. N. (2007). "MicroRNA regulation in the cardiovascular system." Current Opinion in Genetics & Development, 17(5), 516-522. (https://www.sciencedirect.com/science/article/pii/S0959437X07001365)
40. Smith, R. A., et al. (2011). "MicroRNAs in neurodegeneration: Progress and prospects." Nature Reviews Neuroscience, 12(4), 276-288. (https://www.nature.com/articles/nrn3009)
41. Wang, Y., et al. (2010). "MicroRNAs in metabolism." Nature Reviews Endocrinology, 6(9), 531-539. (https://www.nature.com/articles/nrendo201025)
42. Fornari, F., et al. (2017). "Circulating microRNAs in liver diseases." Journal of Hepatology, 67(1), 151-159. (https://www.journal-of-hepatology.eu/article/S0168-8278(17)30454-7/fulltext)
43. Heneghan, H. M., et al. (2010). "Circulating microRNAs: A novel class of biomarkers for cancer detection and prognosis." Cancer Epidemiology, Biomarkers & Prevention, 19(3), 632-639. (https://cebp.aacrjournals.org/content/19/3/632)
44. Ragusa, M., et al. (2020). "MicroRNAs as Biomarkers in Oncology: A Review." Journal of Personalized Medicine, 10(1), 1-12. (https://www.mdpi.com/2075-4426/10/1/1)
45. Thum, T., et al. (2008). "Circulating microRNAs as potential biomarkers of heart failure." European Heart Journal, 29(22), 2877-2884. (https://academic.oup.com/eurheartj/article/29/22/2877/305353)
46. Bader, A. G. (2012). "miR-21: A miRNA that has a role in the pathogenesis of cancer." The American Journal of Pathology, 180(5), 1895-1904. (https://www.sciencedirect.com/science/article/pii/S0002944012000610)
47. Mansoori, B., et al. (2021). "MicroRNA: A new biomarker for diagnosis and treatment of cancer." Biochimica et Biophysica Acta (BBA) – Reviews on Cancer, 1875(2), 188507. (https://www.sciencedirect.com/science/article/pii/S0304419X20302005)
48. Ramesh, N. S., et al. (2021). "Nanoparticle-based delivery of microRNAs: A novel strategy for cancer therapy." Journal of Controlled Release, 329, 977-993. (https://www.sciencedirect.com/science/article/pii/S0168365921001680)
49. Zhao, H., et al. (2020). "Therapeutic efficacy of a let-7 mimic in a mouse model of lung cancer." Molecular Therapy, 28(6), 1468-1480.(https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(20)30114-0)
50. Fabbri, M., et al. (2013). "MicroRNAs and cancer: New paradigms in molecular oncology." The American Journal of Pathology, 182(6), 1930-1936. (https://www.sciencedirect.com/science/article/pii/S0002944013001099)

51. Takamizawa, J., et al. (2004). "Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival." Cancer Research, 64(11), 3753-3756. (https://cancerres.aacrjournals.org/content/64/11/3753)
52. Vannini, I., et al. (2021). "MicroRNA-21 as a potential biomarker of drug resistance in cancer." Current Cancer Drug Targets, 21(1), 42-53. (https://www.eurekaselect.com/109671/article)
53. Li, H., et al. (2016). "MicroRNA-1 regulates cardiac muscle cell differentiation by targeting GATA-4." Journal of Molecular and Cellular Cardiology, 90, 62-74. (https://www.sciencedirect.com/science/article/pii/S0022282816300490)
54. Miyoshi, N., et al. (2011). "The role of microRNAs in the regulation of pluripotency and differentiation in stem cells." Nature Reviews Molecular Cell Biology, 12(10), 758-764. (https://www.nature.com/articles/nrm.2011.97)
55. Pinho, M. G., et al. (2018). "MicroRNA-mediated regulation of stem cell pluripotency and reprogramming." Journal of Stem Cell Research & Therapy, 8(4), 490. (https://www.longdom.org/abstract/microrna-mediated-regulation-of-stem-cell-pluripotency-and-reprogramming-38136.html)
56. Yu, H., et al. (2018). "MicroRNA-mediated control of stem cell fate." Frontiers in Genetics, 9, 242.(https://www.frontiersin.org/articles/10.3389/fgene.2018.00242/full)
57. Zhao, Y., et al. (2017). "MicroRNA-29b regulates the proliferation and differentiation of neural stem cells." Journal of Biological Chemistry, 292(11), 4614-4623. (https://www.jbc.org/article/S0021-9258(20)27105-5/fulltext)
58. Mestdagh, P., et al. (2009). A novel and universal method for microRNA RT-qPCR data normalization. Genome Biology, 10(6), R64. https://doi.org/10.1186/gb-2009-10-6-r64
59. Wang, Z. (2009). The principles of MiRNA-mRNA interactions: Theory, concepts, and applications. Methods in Molecular Biology, 467, 107-126. https://doi.org/10.1007/978-1-59745-241-0_9
60. Kozomara, A., Birgaoanu, M., & Griffiths-Jones, S. (2019). miRBase: from microRNA sequences to function. Nucleic Acids Research, 47(D1), D155-D162. https://doi.org/10.1093/nar/gky1141
61. Friedländer, M. R., et al. (2012). miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Research, 40(1), 37-52. https://doi.org/10.1093/nar/gkr688
62. Lagos-Quintana, M., et al. (2002). Identification of tissue-specific microRNAs from mouse. Current Biology, 12(9), 735-739. https://doi.org/10.1016/S0960-9822(02)00809-6
63. Nagarajan, N., & Pop, M. (2013). Sequence assembly demystified. Nature Reviews Genetics, 14(3), 157-167. https://doi.org/10.1038/nrg3367
64. Ddagh, P., et al. (2009). A novel and universal method for microRNA RT-qPCR data normalization. Genome Biology, 10(6), R64. https://doi.org/10.1186/gb-2009-10-6-r64
65. Zhao, Y., & Srivastava, D. (2007). A developmental view of microRNA function. Trends in Biochemical Sciences, 32(4), 189-197. https://doi.org/10.1016/j.tibs.2007.02.006
66. Prathiba K. Y, Usha S, Suchithra B, Jyothi M. N, Ulfath T. K. S, Sharadamma N, Hoor F. S, . Nageshbabu R. Analysing the Response of Non-Coding RNA of Niger, Guizotia abyssinica Towards High Temperature and Associated Functional Predictions. Biosc.Biotech.Res.Comm. 2020;13(3).
67. Prathiba et al., Computational identification of miRNAs and their targets from Niger (Guizotia abyssinica), Journal of Applied Biology & Biotechnology, Vol. 5 (02), pp. 053-058, March-April, 2017